Try our Advanced Search for more refined results
Life Sciences
-
April 16, 2025
Sterlington Adds Ex-Loeb & Loeb PTAB Trials Head In Calif.
International law firm Sterlington PLLC has added a partner who has guided clients in more than 140 proceedings before the U.S. Patent Trial and Appeal Board, strengthening its intellectual property practice with the former chair of Loeb & Loeb's PTAB trials practice, the firm announced Wednesday.
-
April 16, 2025
Biotech Glycomine Closes $115M Series C Funding Round
Biotechnology company Glycomine Inc. on Wednesday announced that it wrapped its Series C funding round with $115 million in tow to advance its lead candidate into a Phase 2b clinical trial.
-
April 16, 2025
California Challenges Trump's Economic Emergency Tariffs
The California state government filed suit Wednesday challenging President Donald Trump's recent use of a law that has allowed him to unilaterally impose broad and aggressive tariffs on imports entering the U.S.
-
April 15, 2025
Astellas Bladder Drug Patent Survives Following Bench Trial
A Delaware federal judge on Tuesday held that generic-drug makers Lupin and Zydus Pharmaceuticals haven't shown "by clear and convincing evidence" that an Astellas Pharma patent covering the bladder medication Myrbetriq is invalid.
-
April 15, 2025
Biogen, Genentech Head To June Trial Over MS Drug Royalties
A California federal judge on Tuesday denied Biogen's bid for summary judgment in a high-stakes contract fight with Roche Holding AG subsidiary Genentech over patent royalties on multiple sclerosis drug sales, saying during a hearing that there's a material dispute over the contract's language and the case will be tried in June.
-
April 15, 2025
Novo Nordisk Seeks Toss Of Hospital's Insulin Pen Suit
Novo Nordisk has told a Connecticut federal judge that a hospital in the state didn't show that the pharmaceutical company didn't warn nurses that its insulin pens are meant to be used with only one patient in a suit over a $1 million settlement the hospital paid to patients potentially exposed to blood-borne infections.
-
April 15, 2025
Fed. Circ. Won't Revive Stryker Unit's Antiseptic Patents
The Patent Trial and Appeal Board properly invalidated claims in two Sage Products LLC patents for sterilizing antiseptics, the Federal Circuit affirmed Tuesday.
-
April 15, 2025
39 AGs Urge Congress To Ban PBM Pharmacy Ownership
A bipartisan coalition of attorneys general have urged congressional leadership to pass legislation banning pharmacy benefit managers, their parent companies and affiliates from owning and operating pharmacies in order to boost competition and fairness.
-
April 15, 2025
Ga. Woman Says Baby 'Ripped Away' After Embryo Mix-Up
A South Carolina fertility clinic has been hit with a lawsuit from a former patient alleging that its doctors placed the wrong embryo inside her — a fact she discovered only when she, a white woman, gave birth to a Black boy — only to have the baby "ripped away from her" by his biological parents after months of raising him as her own.
-
April 15, 2025
Research Co. Inks $7.15M Deal To End Stock Plan Suit
A genomic research company agreed to pay $7.15 million to resolve a suit claiming it shorted former workers enrolled in an employee stock ownership plan when it required them to sell their shares back to the company, according to filings in Massachusetts federal court.
-
April 15, 2025
Haleon Paying $221M For Full Control Of Chinese Pharma JV
British consumer healthcare company Haleon PLC said Tuesday it has agreed to purchase the remaining 12% stake in its Chinese joint venture, Tianjin TSKF Pharmaceutical Co., for 1.623 billion yuan ($221 million) after increasing its stake to 88% last year.
-
April 15, 2025
Kirkland-Led Linden Wraps $5.4B Healthcare-Focused Fund
Healthcare-focused private equity shop Linden Capital Partners, advised by Kirkland & Ellis LLP, on Tuesday announced that it clinched its sixth fund with $5.4 billion of capital commitments.
-
April 14, 2025
Musk Supports Deleting IP Law, Attorneys Say Let's Not
Elon Musk's endorsement of a terse social media post from tech executive Jack Dorsey saying "delete all IP law" drew scorn from the intellectual property community and was followed by posts from U.S. Patent and Trademark Office acting Director Coke Morgan Stewart extolling the virtues of trademark, patent and copyright protections.
-
April 14, 2025
Fed. Circ. Hears Teva Challenge To J&J Schizophrenia Drug
A Federal Circuit panel on Monday grappled with how to determine whether a dosage patent on Johnson & Johnson's blockbuster schizophrenia drug Invega Sustenna is invalid as obvious, questioning attorneys for the company and generics maker Teva about the proper analysis.
-
April 14, 2025
Juul Seeks Ax of Noncompliant Plaintiffs In E-Cig Suits
Juul on Monday asked a California federal judge to toss claims brought by plaintiffs who failed to comply with court orders, about two years after Juul reached a $255 million global settlement in the litigation.
-
April 14, 2025
Ozempic Pretender On Sale In Conn., Novo Nordisk Says
A Connecticut company is selling compounded drugs that purport to contain semaglutide, the active ingredient in Novo Nordisk medications including Ozempic, and improperly implying that the products are approved by the U.S. Food and Drug Administration, according to a lawsuit that alleges violations of state and federal law.
-
April 14, 2025
J&J Units Beat Patent Suit Over Surgical Screw Designs
A Delaware federal judge has handed Johnson & Johnson subsidiary DePuy Synthes Inc. a win in a patent infringement lawsuit launched by a retired surgeon's patent company over surgical screw technology, finding that the patent claims are too broad and invalid for lack of enablement.
-
April 14, 2025
Women's Healthtech Co. Chiaro Files Ch. 15 In Delaware
British women's healthtech company Chiaro Technology Ltd. has filed for Chapter 15 recognition in Delaware bankruptcy court, seeking acknowledgment of an insolvency proceeding in the United Kingdom through which it aims to manage its American assets while pursuing a sale to a competitor.
-
April 14, 2025
Takeda Gets Actos Case Paused For Class Cert. Review
A New York federal court has paused a lawsuit accusing Takeda Pharmaceuticals of inflating the price of its diabetes treatment, Actos, by delaying the entry of generic alternatives, and took a scheduled July trial off the calendar, as the company appeals a class certification ruling.
-
April 14, 2025
Sandoz Sues Amgen Over Enbrel Biosimilar
Sandoz accused Amgen of illegally blocking biosimilar competition to its blockbuster Enbrel drug for arthritis and other inflammatory diseases, alleging that the company used strategic acquisitions and illegal patent extensions to fend off challengers in the space and inflate U.S. prices for its drug.
-
April 14, 2025
3 Ex-Cooley IP Attys Help Launch New Fenwick Boston Office
Fenwick & West LLP said Monday it has opened a temporary office in Boston with three new intellectual property partners, including Matthew Pavao, Cooley LLP's former global patent prosecution and counseling group chair, with plans to open a permanent space in the future.
-
April 11, 2025
Amgen Can't Ditch Regeneron's Bundling Antitrust Suit
A Delaware federal judge on Thursday denied Amgen's bid to toss antitrust litigation brought by Regeneron accusing its rival of using a bundling scheme to increase the sales of its cholesterol drug Repatha and push competitors out of the market.
-
April 11, 2025
Express Scripts Judge Asks If Khan's FTC Exit Affects Suit
The Missouri federal judge overseeing Express Scripts' lawsuit accusing the Federal Trade Commission of defaming it with a report excoriating the pharmacy benefits manager for allegedly inflating drug costs asked the parties Friday if new leadership at the commission affects the case that significantly targets former Chair Lina Khan.
-
April 11, 2025
Dentsply Brass Face Investor Suit Over Alleged Dental Injuries
Executives and directors of dental supply manufacturing company Dentsply Sirona Inc. have been hit with a derivative suit alleging they concealed that a company subsidiary was approving unsuitable patients for dental treatments to inflate sales figures.
-
April 11, 2025
Tariff Reprieve Offers Little Comfort For Venture-Backed IPOs
President Donald Trump's move to pause most tariff threats is not reassuring venture-backed startups eyeing public listings, many of which will likely postpone initial public offerings for at least another quarter or until shaky market conditions stabilize, a new report concludes.
Expert Analysis
-
Beware Risks Of Arguing Multiple Constructions In IP Cases
Defendants accused of patent infringement often argue for different, potentially contradictory, claim constructions before district courts and the Patent Trial and Appeal Board, but the board may be clamping down on this strategy, say attorneys at Dechert.
-
What's At Stake In High Court Transgender Care Suit
The outcome of U.S. v. Skrmetti will have critical implications for the rights of transgender youth and their access to gender-affirming care, and will likely affect other areas of law and policy involving transgender individuals, including education, employment, healthcare and civil rights, say attorneys at ArentFox Schiff.
-
6th Circ. Ruling Paves Path Out Of Loper Bright 'Twilight Zone'
The U.S. Supreme Court’s Loper Bright ruling created a twilight zone between express statutory delegations that trigger agency deference and implicit ones that do not, but the Sixth Circuit’s recent ruling in Moctezuma-Reyes v. Garland crafted a two-part test for resolving cases within this gray area, say attorneys at Wiley.
-
A Reminder On Avoiding Improper Venues In Patent Cases
A Texas federal court's recent decision in the Symbology and Quantum cases shows that baseless patent venue allegations may be subject to serious Rule 11 sanctions, providing venue-vetting takeaways for plaintiffs and defendants, say attorneys at Bond Schoeneck.
-
NIH Cuts To Indirect Costs May Stifle IP Generation
Although currently blocked by a preliminary injunction, the National Institutes of Health's new policy to cut down on indirect cost funding creates challenges for university research projects, and may hamper the development of intellectual property — which is considered an indirect cost — for years to come, say attorneys at Snell & Wilmer.
-
Recent Cases Clarify FCA Kickback Pleading Standards
Two recently resolved cases involving pharmaceutical manufacturers may make it more difficult for False Claims Act defendants facing kickback scheme allegations to get claims dismissed for lack of evidence, say Li Yu at Bernstein Litowitz, Ellen London at London & Noar, and Gregg Shapiro at Gregg Shapiro Law.
-
Opinion
Antitrust Analysis In Iowa Pathologist Case Misses The Mark
An Iowa federal court erred in its recent decision in Goldfinch Laboratory v. Iowa Pathology Associates by focusing exclusively on market impacts and sidestepping key questions that should be central to antitrust standing analysis, says Daniel Graulich at Baker McKenzie.
-
Opinion
State FCAs Should Cover Local Fund Misuse, State Tax Fraud
New Jersey and other states with similar False Claims Acts should amend them to cover misappropriated municipal funding, and state and local tax fraud, which would encourage more whistleblowers to come forward and increase their recoveries, says Kenneth Levine at Stone & Magnanini.
-
7 Tips For Associates To Thrive In Hybrid Work Environments
Excerpt from Practical Guidance
As the vast majority of law firms have embraced some type of hybrid work policy, associates should consider a few strategies to get the most out of both their in-person and remote workdays, says James Argionis at Cozen O’Connor.
-
Series
Playing Beach Volleyball Makes Me A Better Lawyer
My commitment to beach volleyball has become integral to my performance as an attorney, with the sport continually reminding me that teamwork, perseverance, professionalism and stress management are essential to both undertakings, says Amy Drushal at Trenam.
-
What To Expect From 'Make America Healthy Again' Actions
The Make America Healthy Again Commission recently established by President Donald Trump and chaired by Robert F. Kennedy Jr. will potentially bring energy and attention to important public health topics, and stakeholders should be aware of pathways for sharing their input and proactively informing proceedings, says Nicholas Manetto at Faegre Drinker.
-
How Law Firms Can Counteract The Loneliness Epidemic
The legal industry is facing an urgent epidemic of loneliness, affecting lawyer well-being, productivity, retention and profitability, and law firm leaders should take concrete steps to encourage the development of genuine workplace connections, says Michelle Gomez at Littler and Gwen Mellor Romans at Herald Talent.
-
What's At Stake In High Court's Class Member Standing Case
The U.S. Supreme Court’s eventual decision in Labcorp v. Davis could significantly alter how parties prosecute and defend class actions in federal court, particularly if the court determines some proof of member standing is required before a class may be certified, say attorneys at Reed Smith.
-
How Citizen Petitions Have Affected Drug Competition
In light of recent citizen petitions and proposed legislation regulating such petitions, Omar Robles at Managing Health analyzes the statistics of the extent to which citizen petitions have been filed, and to what extent they have delayed competition in prescription pharmaceuticals.
-
5 Keys To Building Stronger Attorney-Client Relationships
Attorneys are often focused on being seen as the expert, but bonding with clients and prospects by sharing a few key personal details provides the basis for a caring, trusted and profoundly deeper business relationship, says Deb Feder at Feder Development.